WallStreetZenWallStreetZen

NASDAQ: ATTO
Attovia Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ATTO

Based on 4 analysts offering 12 month price targets for Attovia Therapeutics Inc

Min Forecast
$34.00+104.33%
Avg Forecast
$42.75+156.91%
Max Forecast
$52.00+212.5%

Should I buy or sell ATTO stock?

Based on 4 analysts offering ratings for Attovia Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ATTO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ATTO as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their ATTO stock forecasts and price targets.

ATTO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-11-10
lockedlocked$00.00+00.00%2026-11-10
lockedlocked$00.00+00.00%2026-08-31
lockedlocked$00.00+00.00%2026-08-31
lockedlocked$00.00+00.00%2026-08-31

1 of 1

Forecast return on equity

Is ATTO forecast to generate an efficient return?

Company
-28.67%
Industry
-27.68%
Market
144.04%
ATTO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ATTO forecast to generate an efficient return on assets?

Company
-27.69%
Industry
-3.96%
ATTO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ATTO earnings per share forecast

What is ATTO's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$3.01
Avg 2 year Forecast
-$2.21
Avg 3 year Forecast
-$2.49

ATTO revenue forecast

What is ATTO's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$471.8k
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ATTO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATTO$16.64$42.75+156.91%Strong Buy
ARDX$3.01$12.00+298.67%Strong Buy
ABUS$3.82N/AN/A
OABI$5.10$9.67+89.55%Strong Buy
DNA$12.01$8.00-33.39%Sell
View Top Biotech Stocks

Attovia Therapeutics Stock Forecast FAQ

Is Attovia Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ATTO) stock is to Strong Buy ATTO stock.

Out of 4 analysts, 2 (50%) are recommending ATTO as a Strong Buy, 2 (50%) are recommending ATTO as a Buy, 0 (0%) are recommending ATTO as a Hold, 0 (0%) are recommending ATTO as a Sell, and 0 (0%) are recommending ATTO as a Strong Sell.

If you're new to stock investing, here's how to buy Attovia Therapeutics stock.

What is ATTO's earnings growth forecast for 2026-2028?

(NASDAQ: ATTO) Attovia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.75%.

Attovia Therapeutics's earnings in 2026 is N/A.On average, 6 Wall Street analysts forecast ATTO's earnings for 2026 to be -$137,384,456, with the lowest ATTO earnings forecast at -$181,881,038, and the highest ATTO earnings forecast at -$99,164,204. On average, 6 Wall Street analysts forecast ATTO's earnings for 2027 to be -$101,029,276, with the lowest ATTO earnings forecast at -$106,619,919, and the highest ATTO earnings forecast at -$84,330,486.

In 2028, ATTO is forecast to generate -$114,016,207 in earnings, with the lowest earnings forecast at -$122,747,302 and the highest earnings forecast at -$100,366,444.

What is ATTO's revenue growth forecast for 2026-2028?

(NASDAQ: ATTO) Attovia Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.76%.

Attovia Therapeutics's revenue in 2026 is N/A.On average, 6 Wall Street analysts forecast ATTO's revenue for 2026 to be $21,564,889, with the lowest ATTO revenue forecast at $20,159,228, and the highest ATTO revenue forecast at $23,999,081. On average, 5 Wall Street analysts forecast ATTO's revenue for 2027 to be $0, with the lowest ATTO revenue forecast at $0, and the highest ATTO revenue forecast at $0.

In 2028, ATTO is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ATTO's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: ATTO) forecast ROA is -27.69%, which is lower than the forecast US Biotechnology industry average of -3.96%.

What is ATTO's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ATTO price target, the average ATTO price target is $42.75, with the highest ATTO stock price forecast at $52.00 and the lowest ATTO stock price forecast at $34.00.

On average, Wall Street analysts predict that Attovia Therapeutics's share price could reach $42.75 by Nov 10, 2027. The average Attovia Therapeutics stock price prediction forecasts a potential upside of 156.91% from the current ATTO share price of $16.64.

What is ATTO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ATTO) Attovia Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that ATTO's EPS will be -$3.01 for 2026, with the lowest EPS forecast at -$3.98, and the highest EPS forecast at -$2.17. On average, analysts forecast that ATTO's EPS will be -$2.21 for 2027, with the lowest EPS forecast at -$2.33, and the highest EPS forecast at -$1.84. In 2028, ATTO's EPS is forecast to hit -$2.49 (min: -$2.69, max: -$2.20).

What is ATTO's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: ATTO) forecast ROE is -28.67%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.